<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935712</url>
  </required_header>
  <id_info>
    <org_study_id>D9150C00001</org_study_id>
    <secondary_id>2016-002316-40</secondary_id>
    <nct_id>NCT02935712</nct_id>
  </id_info>
  <brief_title>Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Phase I, Randomized, Single-Blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacodynamics Of AZD8601 After Single Dose Administration to Male Patients With Type II Diabetes Mellitus (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spandauer Damm 130</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>14050</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a phase I, first time in human (FiH), randomized, single-blind,&#xD;
      placebo-controlled, SAD study in male patients with T2DM, performed at a single study center.&#xD;
      The study will consist of 2 parts, (A and B) up to 60 male patients with T2DM aged 18 to 65&#xD;
      years will be included&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part A will assess the safety and tolerability of SAD of intradermal (ID) injection of&#xD;
      AZD8601 (modified VEGF-A RNA) and Part B will evaluate the pharmacodynamic effects of ID&#xD;
      injection of AZD8601 in forearm skin. AZD8601 is a VEGF-A modified RNA under development as a&#xD;
      novel modality for local production of human VEGF-A protein and is developed for the&#xD;
      treatment of diabetic patients with ulcers. Each patient in Part A will be involved in the&#xD;
      study for 7 to 8 weeks. Each patient in Part B will be involved in the study for 5 to 6&#xD;
      weeks.&#xD;
&#xD;
      Safety and tolerability variables includes Adverse events (AEs), Vital signs (BP, pulse),&#xD;
      ECG, Hematology, Clinical chemistry, Urinalysis.&#xD;
&#xD;
      The study will include patients with T2DM that are on stable doses of 1 to 2 anti-diabetic&#xD;
      medications. The T2DM patients may also be on medications for comorbidities such as&#xD;
      hypertension, dyslipidemia, hyperuricemia, thyroid disorders, benign prostate hyperplasia&#xD;
      etc. (e.g. diuretics, statins, allopurinol, thyroxin), but must be healthy otherwise.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 16, 2016</start_date>
  <completion_date type="Actual">January 8, 2018</completion_date>
  <primary_completion_date type="Actual">August 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing summary of adverse events (Part A)</measure>
    <time_frame>Part A: From screening (Day -28) up to Day 29</time_frame>
    <description>To evaluate the safety by assessing the adverse event after administration of a single dose of AZD8601 to male subjects with T2DM (Part A).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with clinically significant blood pressure (Part A)</measure>
    <time_frame>Part A: Day 1 to Day 8</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant blood pressure after administration of single dose of AZD8601 to male subjects with T2DM (Part A).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with Clinically significant pulse (Part A)</measure>
    <time_frame>Part A: Day 1 to Day 8</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant pulse after administration of single dose of AZD8601 to male subjects with T2DM (Part A).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with Clinically significant 12-lead electrocardiograms (ECGs) (Part A)</measure>
    <time_frame>Part A: Day 1 to Day 8</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant ECGs after administration of single dose of AZD8601 to male subjects with T2DM (Part A).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with clinically significant hematology parameters (Part A)</measure>
    <time_frame>Part A: Day 1 to Day 8</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant hematology parameters after administration of single dose of AZD8601 to male subjects with T2DM (Part A).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with clinically significant clinical chemistry laboratory results (Part A)</measure>
    <time_frame>Part A: Day 1 to Day 8</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant clinical chemistry laboratory results after administration of single dose of AZD8601 to male subjects with T2DM (Part A).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with clinically significant urinalysis (Part A)</measure>
    <time_frame>Part A: Day 1 to Day 8</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant urinalysis after administration of single dose of AZD8601 to male subjects with T2DM (Part A).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing summary of adverse events (Part B)</measure>
    <time_frame>Part B: From screening up to Day 15</time_frame>
    <description>To evaluate the safety by assessing the adverse event after administration of a single dose of AZD8601 to male subjects with T2DM (Part B).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with clinically significant blood pressure (Part B)</measure>
    <time_frame>Part B: Day 1 to Day 2</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant blood pressure after administration of single dose of AZD8601 to male subjects with T2DM (Part B).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with Clinically significant pulse (Part B)</measure>
    <time_frame>Part B: Day 1 to Day 2</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant pulse after administration of single dose of AZD8601 to male subjects with T2DM (Part B).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with Clinically significant 12-lead electrocardiograms (ECGs) (Part B)</measure>
    <time_frame>Part B: Day 1 to Day 2</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant ECGs after administration of single dose of AZD8601 to male subjects with T2DM (Part B).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with clinically significant hematology parameters (Part B)</measure>
    <time_frame>Part B: Day 1 to Day 2</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant hematology parameters after administration of single dose of AZD8601 to male subjects with T2DM (Part B).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with clinically significant clinical chemistry laboratory results (Part B)</measure>
    <time_frame>Part B: Day 1 to Day 2</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant clinical chemistry laboratory results after administration of single dose of AZD8601 to male subjects with T2DM (Part B).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of AZD8601 by assessing number of subjects with clinically significant urinalysis (Part B)</measure>
    <time_frame>Part B: Day 1 to Day 2</time_frame>
    <description>To evaluate the safety by assessing the number of subjects with clinically significant urinalysis after administration of single dose of AZD8601 to male subjects with T2DM (Part B).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Male Subjects With Type II Diabetes (T2DM)</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three cohorts with 9 subjects and each cohort received 2 treatments (AZD8601+Placebo/ Placebo+Placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 2 treatments (AZD8601+Placebo)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8601+Placebo (SAD)</intervention_name>
    <description>Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.&#xD;
Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg.</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD8601+Placebo</intervention_name>
    <description>Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.</description>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo+Placebo</intervention_name>
    <description>Subjects are randomized to receive 2 placebo treatments.</description>
    <arm_group_label>Part A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated, written informed consent prior to any study specific&#xD;
             procedures.&#xD;
&#xD;
          2. Male patients with mild T2DM aged 18 to 65 years with suitable veins for cannulation&#xD;
             or repeated venipuncture.&#xD;
&#xD;
          3. Have a body mass index (BMI) between 20 and 35 kg/m2 inclusive and weigh at least 50&#xD;
             kg.&#xD;
&#xD;
          4. Able to understand, read and speak the German language.&#xD;
&#xD;
          5. T2DM diagnosis for at least 1 year at the time of the screening visit.&#xD;
&#xD;
          6. T2DM treated with diet and exercise alone or with up to 2 oral anti-diabetic drugs.&#xD;
&#xD;
          7. Have stable glycemic control indicated by no changed treatment within 3 months prior&#xD;
             to enrolment.&#xD;
&#xD;
          8. Hemoglobin A1c less than 10.5% at screening (HbA1c value according to international&#xD;
             Diabetes Control and Complications Trial standard).&#xD;
&#xD;
          9. Fasting plasma glucose â‰¤ 11.0 mmol/L at screening.&#xD;
&#xD;
         10. Provision of signed, written and dated informed consent for optional genetic/biomarker&#xD;
             research.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any clinically significant disease or disorder which, in the opinion of the&#xD;
             PI, may either put the patient at risk because of participation in the study, or&#xD;
             influence the results or the patient's ability to participate in the study.&#xD;
&#xD;
          2. Any clinically significant illness, medical/surgical procedure, or trauma within 4&#xD;
             weeks of the before Day -1&#xD;
&#xD;
          3. Any clinically significant abnormalities in clinical chemistry, hematology or&#xD;
             urinalysis results at screening and check-in, as judged by the PI.&#xD;
&#xD;
             The following strict criteria will apply at the time of screening and on Day -1:&#xD;
&#xD;
               -  Alanine aminotransferase (ALT), aspartate aminotransferase (AST) &gt; 2 times the&#xD;
                  upper limit of the normal laboratory range&#xD;
&#xD;
               -  Hemoglobin &lt; 11 g/dL and/or neutrophils &lt; 1500/mm3 and/or platelets &lt; 100 000/mm3&#xD;
&#xD;
               -  Creatinine &gt; 1.2 x upper limit of normal (ULN)&#xD;
&#xD;
          4. Uncontrolled or inadequately controlled hypertension at the time of screening and/or&#xD;
             on Day -1 with a resting systolic or diastolic BP &gt; 150 mmHg or &gt; 95 mmHg,&#xD;
             respectively. Patients with heart rate &lt; 50 bpm at screening and on Day -1 will be&#xD;
             excluded.&#xD;
&#xD;
          5. Any clinically significant abnormalities on 12-lead ECG at screening as judged by the&#xD;
             PI.&#xD;
&#xD;
          6. Any patient with QT interval corrected for heart rate using Fridericia's formula&#xD;
             (QTcF) &gt; 450 ms at screening should be excluded.&#xD;
&#xD;
          7. Any positive result on screening for serum hepatitis B surface antigen (HBsAg),&#xD;
             anti-hepatitis B core (HBc) antibody, hepatitis C antibody and human immunodeficiency&#xD;
             virus (HIV) antibody.&#xD;
&#xD;
          8. Has received another new chemical entity (defined as a compound which has not been&#xD;
             approved for marketing) within 3 months of Day -1 of this study. The period of&#xD;
             exclusion begins 3 months after the final dose from a previous study or 1 month after&#xD;
             the last visit, whichever is longer. 9. Plasma donation within 1 month of screening or&#xD;
             any blood donation/loss more than 400 mL during the 3 months prior to screening.&#xD;
&#xD;
        10. Current smokers or those who have smoked or used nicotine products within the previous&#xD;
        1 year cotinine below the cut-off of the local laboratory).&#xD;
&#xD;
        11. Positive screen for drugs of abuse, cotinine or alcohol at screening or admission to&#xD;
        the study center.&#xD;
&#xD;
        12. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as&#xD;
        judged by the PI.&#xD;
&#xD;
        13. Use of any prescribed or non-prescribed medication including antacids, analgesics&#xD;
        (other than paracetamol/ acetaminophen), herbal remedies, mega-dose vitamins (intake of 20&#xD;
        to 600 times the recommended daily dose) and minerals during the 2 weeks prior to admission&#xD;
        or longer if the medication has a long half-life.&#xD;
&#xD;
        Patients with T2DM can be on 1 to 2 anti-diabetic medications but need the medication to be&#xD;
        on stable doses for at least 3 months. Patients with T2DM can also be on medications for&#xD;
        comorbidities such as hypertension, dyslipidemia, hyperuricemia, thyroid disorders, benign&#xD;
        prostate hyperplasia etc. (e.g. diuretics, statins, allopurinol, thyroxin) but need to be&#xD;
        on a stable dose for at least 3 months.&#xD;
&#xD;
        14. Involvement of any AstraZeneca or study site employee or their close relatives.&#xD;
&#xD;
        15. Judgment by the PI that the patient should not participate in the study if they have&#xD;
        any ongoing or recent (i.e., during the screening period) minor medical complaints that may&#xD;
        interfere with the interpretation of study data or are considered unlikely to comply with&#xD;
        study procedures, restrictions and requirements.&#xD;
&#xD;
        16. Vulnerable patients, e.g., kept in detention, protected adults under guardianship,&#xD;
        trusteeship or committed to an institution by governmental or juridical order.&#xD;
&#xD;
        17. Reports a significant history of allergy to soaps, lotions, emollients, ointments,&#xD;
        creams, cosmetics, adhesives or latex.&#xD;
&#xD;
        18. Reports a history of significant skin conditions or disorders, for example, psoriasis,&#xD;
        atopic dermatitis, etc.&#xD;
&#xD;
        19. Reports a history of significant dermatologic cancers, for example, melanoma or&#xD;
        squamous cell carcinoma. Basal cell carcinomas that were superficial or successfully&#xD;
        removed or treated, and do not involve the investigative site are acceptable.&#xD;
&#xD;
        20. Presence of forearm tattoo(s). 21. History of metabolic acidosis, including diabetic&#xD;
        ketoacidosis within 1 year prior to screening.&#xD;
&#xD;
        22. History of myocardial infarction, stroke, or heart failure requiring hospitalization&#xD;
        within 6 months prior to the time of screening, history or presence of clinically&#xD;
        significant diabetic retinopathy, history or presence of macular edema likely to require&#xD;
        LASER treatment within the study period.&#xD;
&#xD;
        23. Uncontrolled cardiovascular, hepatic, neurological or endocrine disease. 24. Use of&#xD;
        insulin, glitazones, warfarin and amiodarone within 3 months before enrolment and use of&#xD;
        potent CYP450 inhibitors, e.g., ketoconazole and macrolide antibiotics within 14 days&#xD;
        before screening.&#xD;
&#xD;
        25. Use of anabolic steroids and systemic treatment with glucocorticoids within 3 months&#xD;
        before screening.&#xD;
&#xD;
        26. Excessive intake of caffeine containing drinks or food (e.g., coffee, tea, chocolate),&#xD;
        as judged by the PI 27. Patients who cannot communicate reliably with the PI. In addition,&#xD;
        any of the following is regarded as a criterion for exclusion from the genetic research:&#xD;
        28. Previous bone marrow transplant 29. Non-leukocyte depleted whole blood transfusion&#xD;
        within 120 days of the date of the genetic sample collection&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainard Fuhr, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Early Phase Clinical Unit, PAREXEL International GmbH, Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>August 18, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <last_update_submitted>January 15, 2020</last_update_submitted>
  <last_update_submitted_qc>January 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>AZD8601</keyword>
  <keyword>Type II Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

